Metformin-pretreated synovial mesenchymal stem cell-derived exosomes alleviate osteoarthritis via the miR-1208/METTL3/NLRP3 axis
Metformin-pretreated SMSCs enhance the anti-inflammatory and chondroprotective properties of their secreted exosomes, primarily through the miR-1208-mediated METTL3/NLRP3 signaling pathway. M-EVs offer an innovative, safe, and potentially translatable acellular therapeutic strategy for OA treatment.
Authors
- Jianxiong Zheng
- Yi Jiang (ORCID: https://orcid.org/0000-0002-9972-568X)
- Quanbo Zhang (ORCID: https://orcid.org/0000-0003-3337-3842)
- Shun-Bing Wang
- Xin Tu (ORCID: https://orcid.org/0009-0000-8477-3382)
- Y. M. Ni (ORCID: https://orcid.org/0009-0003-8013-2918)
- Ruo Er-Li
- Yu-Feng Qing
- Ao Duan
Institutions
- North Sichuan Medical University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1186/s12951-026-04129-3
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00